Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Directional Coordinated Reset Deep Brain Stimulation (DBS)

Technology #20180061

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Deep brain stimulation (DBS) therapiesDBS electrodeNovel stimulation strategy delivers high intensity CR DBS: first to lower the clinical score of Parkinson’s symptoms (UPDRS), then followed by low intensity CR DBS to maintain therapeutic effect
Categories
Researchers
Jing Wang, PhD
Assistant Professor, Department of Neurology
External Link (nmrc.umn.edu)
Gregory F. Molnar, PhD
Associate Professor, Department of Neurology
External Link (nmrc.umn.edu)
Jerrold Vitek, MD, PhD
Professor and Chair, Department of Neurology
External Link (www.neuroscience.umn.edu)
Managed By
Kevin Nickels
Technology Licensing Officer 612-625-7289
Patent Protection

US Patent Pending

Segmented DBS array with variable intensity stimulation

This technology is a system for coordinated reset deep brain stimulation (CR DBS) which uses a segmented DBS array electrodes and short-term electrical pulses delivered in a fixed or varying sequence. This therapy uses multiple contacts in different locations of the target brain structure to offer flexibility to CR contact configuration and intensity selection. In some cases, this can also provide flexibility to cross structure CR configuration. In addition, a novel stimulation strategy delivers high stimulation intensity at the beginning of treatment, until optimal therapeutic improvement is achieved, and then reduces the stimulation to a low intensity to maintain the therapeutic effect. Directional CR DBS could be used to treat nervous system or multiple movement disorders (e.g., Parkinson's disease, essential tremor, dystonia, and other neurological and/or psychiatric conditions).

Low stimulation intensity reduces power consumption

Traditional isochronal DBS, while a successful treatment for Parkinson's disease, has not changed for decades. Constant high frequency stimulation from the traditional DBS drains the device battery within several years, requiring risky battery replacement surgeries. In addition, current spread related side effects limit its application and therapeutic window. Directional CR DBS combines new DBS lead technology and a novel strategy to produce a comparable—or even better—therapeutic effect than traditional DBS therapies and with fewer side effects. Because it uses a very low stimulation intensity (one third or less than traditional isochronal DBS), it significantly reduces battery consumption.

Phase of Development

  • Proof of concept. Preliminary pre-clinical test in non-human primate.

Benefits

  • Provides comparable—or even better—therapeutic effects than traditional DBS therapies
  • Fewer current spread related side effects
  • Reduced power consumption allowing for longer battery life or smaller battery
  • Flexibility to cross structure CR configuration

Features

  • Directional coordinated reset deep brain stimulation (Directional CR DBS)
  • Delivers short-term electrical pulses in a fixed or varying sequence using a segmented DBS array
  • Novel stimulation strategy - high stimulation at beginning of treatment, then reduces stimulation to maintain therapeutic effect

Applications

  • Deep brain stimulation (DBS)
  • Nervous system or multiple movement disorders (e.g., Parkinson's disease, essential tremor, dystonia, and other neurological and/or psychiatric conditions)


Interested in Licensing?
The University relies on industry partners to further develop and ultimately commercialize this technology. The license is for the sale, manufacture or use of products claimed by the patents. Please contact Kevin Nickels to share your business needs and licensing and technical interests in this technology.